• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

$3,995.00 – $7,990.00

Clear
SKU: KLI1646591 Categories: Pharmaceuticals Market Research, Vaccines Market Reports Pages: 250
  • Description
  • Table of Contents
  • Latest reports

Description

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.

There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products.
Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis.

In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

  • Melonoma Vaccines
  • Lung Cancer Vaccines
  • Prostate Cancer Vaccines
  • Cervical Cancer Vaccines
  • Brain Cancer Vaccines
  • Colon/Rectal Cancer Vaccines
  • Breast Cancer Vaccines
  • Lymphoma Vaccines
  • Ovarian Cancer Vaccines
  • Leukemia Vaccines
  • Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:

  • Forecasts for Future Revenues from Cancer Vaccines
  • Cancer Epidemiology
  • Reviews of Products in the Pipeline
  • Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
  • Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:

  • Introduction
  • Early Detection and Screening
  • Monoclonal Antibodies and Therapeutic Vaccines
  • Political and Social Pressure
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine Strategies
  • New Genetic Technique
  • Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

  • Antigenics, Inc.
  • Avax Technologies, Inc.
  • Biovest International, Inc.
  • Cell Genesys, Inc.
  • Dendreon Corporation
  • Genitope Corporation
  • GlaxoSmithKline plc
  • Merck & Company, Inc.
  • Northwest Biotherapeutics, Inc.
  • NovaRx
  • Oncothyreon
  • Vaccinogen
  • Vical, Inc.

Table of Contents

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Size and Growth of the Market

Issues and Trends Affecting Market

Leading Competitors

CHAPTER TWO: INTRODUCTION

Introduction

History and Growth of the Cancer Treatment Market

Types of Vaccines

Antigen/Adjuvant Vaccines

Whole Cell Tumor Vaccines

Dendritic Cell (DC) Vaccines

Viral Vectors and DNA Vaccines

Idiotype Vaccines

Types of Therapeutic Vaccines

Patient-Specific Vaccines

Prostate Specific Antigen

Sialyl Tn

Heat Shock Proteins

Ganglioside Molecules

Carcinoembryonic Antigen (CEA)

MART-1

Tyrosinase

Adjuvants

Industry Structure

Demographics and Statistics

Growing and Aging Population

Life Expectancy and Cancer

CHAPTER THREE: CERVICAL CANCER VACCINES

Overview

Description of Vaccines on the Market

Gardasil/Silgard

Cervarix

Description of Vaccines in Development

TG 4001/R3484

HspE7

Lovaxin C

VGX-3100

CA-9

Market Summary

Current and Potential Competitors and Analysis, 2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

Overview

Description of Vaccines on the Market

OncoVAX

Description of Vaccines in Development

OncoVAX

TroVAX

Avicine

CEA VRP Vaccine

Collidem

IMA910

Lapuleucel-T

Oncophage

CDX-1307-01

Tumor Associated Antigen Therapeutic Vaccine – CEA DNA Cancer Vaccine

MKC1106-PP

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER FIVE: LUNG CANCER VACCINES

Overview

Description of Vaccines in Development

Lucanix

MAGE-A3 Peptide

Stimuvax

EGF Cancer Vaccine

GV-1001

HyperAcute Lung

IDM 2101 (EP-2101)

Oncophage

INGN 225

TG 4010

LungVAX

Tumor Associated Antigen Therapeutic Vaccine – CEA DNA Cancer Vaccine

DC Vax

L523S

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER SIX: LYMPHOMA VACCINES

Overview

Description of Vaccines in Development

MyVax

BiovaxID

FavId

TG 1042

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER SEVEN: MELANOMA VACCINES

Overview

Description of Vaccines on the Market

Description of Vaccines in Development

M-VAX

GMK

Allovectin-7

MDX-1379 with Combination Treatment MDX-010

Oncophage

MAGE-A3 ASCI 3

Uvidem

AGI-101H Vaccine

ALVAC Vaccine

HyperAcute Melanoma

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES

Overview

Description of Vaccines in Development

Provenge

DCVax-Prostate

GVAX

ProstAtak

TroVAX

Telomerase Cancer Vaccine

MVA-BN Prostate

HyperAcute Prostate

MKC1106-PP

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER NINE: BREAST CANCER VACCINES

Overview

Description of Vaccines in Development

INGN 225

CEA VRP Vaccine

MVA-BN HER2

Lapuleucel-T

PX 104.1

CDX-1307-02

Tumor Associated Antigen Therapeutic Vaccine – CEA DNA Cancer Vaccine

MKC1106-PP

Market Summary

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

Overview

Description of Vaccines in Development

GV 1001

GI-4000

Avicine

GVAX

HyperAcute Pancreas

Oncophage

CDX-1307-01

CRS-100

CRS-207

DC Vax

MKC1106-PP

Market Summary

CHAPTER ELEVEN: RENAL CANCER VACCINES

Overview

Description of Vaccines on the Market

Oncophage

Description of Vaccines in Development

Oncophage

Reniale

TroVAX

IMA901

AGS-003

MDX-1106

MKC1106-PP

Market Summary

Potential Competitors and Analysis, 2012

CHAPTER TWELVE: BRAIN CANCER VACCINES

Overview

Glioblastoma

Neuroblastoma

Description of Vaccines in Development

DCVax-Brain

CDX-110

GliAtak

Oncophage

Market Summary

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

Overview

Description of Vaccines on the Market

BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)

Description of Vaccines in Development

Bexidem

CG0070

MDX-1307-01

Market Summary

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

Overview

Description of Vaccines in Development

OVax Autologous Cell Vaccine

Lapuleucel-T

Tumor Associated Antigen Therapeutic Vaccine – CEA DNA Cancer Vaccine

MKC1106-PP

Market Summary

CHAPTER FIFTEEN: LEUKEMIA VACCINES

Overview

Description of Vaccines in Development

GVAX

PR1 Peptide Vaccine

AGS-005

Market Summary

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

Introduction

Early Detection and Screening

Monoclonal Antibodies and Therapeutic Vaccines

Political and Social Pressure

Insurance and Reimbursement Issues

Personalized Medicine

Pharmacogenomics

Vaccine Strategies

New Genetic Technique

Future Growth in Vaccines

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

Overview

Total Market Size and Forecast

Market and Competitor Analysis

CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES

Introduction

Antigenics, Inc

Avax Technologies, Inc

Biovest International, Inc

Cell Genesys, Inc

Dendreon Corporation

Genitope Corporation

GlaxoSmithKline plc

Merck & Company, Inc

Northwest Biotherapeutics, Inc

NovaRx

Oncothyreon

Vaccinogen

Vical, Inc

CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

 

  • Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
  • Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012

 

CHAPTER TWO: INTRODUCTION

 

  • Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
  • Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
  • Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
  • Figure 2-2: Total Cancer Incidence by Sex and Country
  • Table 2-3: World Population by Selected Geographical Region, 2007-2050
  • Figure 2-4: World Population by Selected Geographical Region, 2007-2050
  • Table 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
  • Table 2-5: Percent Population Over 65 by Year and Region
  • Figure 2-5: Estimated World Population by Age, 2007 and 2050
  • Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
  • Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
  • Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

 

CHAPTER THREE: CERVICAL CANCER VACCINES

 

  • Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
  • Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
  • Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
  • Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
  • Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
  • Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012

 

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

 

  • Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
  • Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
  • Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
  • Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
  • Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
  • Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012

 

CHAPTER FIVE: LUNG CANCER VACCINES

 

  • Table 5-1: Types of Primary Lung Cancer
  • Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
  • Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
  • Table 5-3: Lung Cancer Vaccines in the Pipeline

 

CHAPTER SIX: LYMPHOMA VACCINES

 

  • Table 6-1: Classification of Non-Hodgkin’s Lymphomas
  • Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
  • Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
  • Table 6-3: Lymphoma Vaccines in the Pipeline
  • Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
  • Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
  • Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012

 

CHAPTER SEVEN: MELANOMA VACCINES

 

  • Table 7-1: Malignant Condidtions of the Skin
  • Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
  • Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
  • Table 7-3: Melanoma Vaccines in the Pipeline
  • Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
  • Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
  • Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012

 

CHAPTER EIGHT: PROSTATE CANCER VACCINES

 

  • Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
  • Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
  • Table 8-2: Prostate Cancer Vaccines in the Pipeline
  • Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
  • Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
  • Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012

 

CHAPTER NINE: BREAST CANCER VACCINES

 

  • Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
  • Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
  • Table 9-2: Breast Cancer Vaccines in the Pipeline

 

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

 

  • Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
  • Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
  • Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline

 

CHAPTER ELEVEN: RENAL CANCER VACCINES

 

  • Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
  • Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
  • Table 11-2: Renal Cancer Vaccines in the Pipeline
  • Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
  • Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
  • Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
  • Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012

 

CHAPTER TWELVE: BRAIN CANCER VACCINES

 

  • Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
  • Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
  • Table 12-2: Brain Cancer Vaccines in the Pipeline

 

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

 

  • Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
  • Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
  • Table 13-2: Bladder Cancer Vaccines in the Pipeline

 

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

 

  • Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
  • Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
  • Table 14-2: Ovarian Cancer Vaccines in the Pipeline

 

CHAPTER FIFETEEN: LEUKEMIA VACCINES

 

  • Table 15-1: TYPES OF LEUKEMIA
  • Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
  • Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
  • Table 15-3: Leukemia Vaccines in the Pipeline

 

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

 

  • Table 16-1: Cancer Detection Tests

 

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

 

  • Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012
  • Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
  • Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012

 

CANCER VACCINE CORPORATE PROFILES

COMPANY NAMES AND ADDRESSES

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Market for Rx-to-OTC Switches, 3rd Edition, The

    $2,625.00 – $5,250.00
  • Placeholder image

    Rheumatoid Arthritis: The 45 Market in the United States for Drugs and Biologics

    $2,246.00 – $4,492.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00
  • Placeholder image

    Growth Factors: Indications, Products, and Markets

    $2,625.00 – $5,250.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis...Glucose Testing Markets
Scroll to top